Original Research

Defining oligometastatic non-small cell lung cancer: A simulated multidisciplinary expert opinion

Lizza E.L. Hendriks a,b,*, Christophe Dooms c, Thierry Berghmans d, Silvia Novello e, Antonin Levy b,f, Dirk De Ruysscher g, Baktiar Hasan h, Matteo Giaj Levra b,i, Niccolo Giaj Levra b,i,k, Benjamin Besse l, Johan Vansteenkiste c, Anne-Marie C. Dingemans a on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) Lung Cancer Group

a Department of Pulmonary Diseases, GROW - School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, the Netherlands
b Young Investigators EORTC Lung Cancer Group (YI EORTC LCG), Belgium
c Respiratory Oncology Unit, Department of Respiratory Diseases KU Leuven, Leuven, Belgium
d Department of Intensive Care and Oncological Emergencies & Thoracic Oncology, Institut Jules Bordet, Université Libre de Bruxelles, Brussels, Belgium
e Oncology Department, University of Turin, AOU San Luigi, Orbassano (TO), Italy
f Department of Radiation Oncology, Gustave Roussy, Institut D’Oncologie Thoracique (IOT), INSERM U1030, Université Paris-Saclay, F-94805, Villejuif, France
i Respiratory Oncology Unit, Department of Thoracic and Vascular Disease, CHU Grenoble Alpes, Grenoble, France
i Department of Radiation Oncology, IRCCS Sacro Cuore Don Calabria Hospital, Negrar, Verona, Italy
k Department of Oncology, University of Turin, Torino, Italy
I Department of Cancer Medicine, Institut D’Oncologie Thoracique (IOT), Gustave Roussy, Université Paris-Saclay, F-94805, Villejuif, France

Received 23 July 2019; received in revised form 28 August 2019; accepted 6 September 2019
Available online 23 October 2019

* Corresponding author. Dept. of Pulmonary Diseases, GROW - School for oncology and developmental biology, Maastricht University Medical Center+, PO Box 5800, 6202 AZ, Maastricht, the Netherlands. Fax: +31-(0)43875051.
E-mail addresses: lizza.hendriks@mumc.nl (L.E.L. Hendriks), Christophe.dooms@uzleuven.be (C. Dooms), Thierry.berghmans@bordet.be (T. Berghmans), Silvia.novello@unito.it (S. Novello), Antonin.LEVY@gustaveroussy.fr (A. Levy), Dirk.deruysscher@maastro.nl (D. De Ruysscher), Baktiar.hasan@eortc.org (B. Hasan), mgiajlevra@chu-grenoble.fr (M. Giaj Levra), niccolo.giajlevra@sacrocuore.it (N. Giaj Levra), Benjamin.BESSE@gustaveroussy.fr (B. Besse), Johan.vansteenkiste@uzleuven.be (J. Vansteenkiste), a.dingemans@mumc.nl (A.-M.C. Dingemans).

https://doi.org/10.1016/j.ejca.2019.09.013
0959-8049/© 2020 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
1. Introduction

Patients with metastasised non-small cell lung cancer (NSCLC) are generally considered incurable. However, it is suggested that some patients have an intermediate state, between localised disease and widespread metastases, and that they could benefit from more aggressive treatment. The term ‘oligometastases’ has first been proposed in 1995 by Hellman et al. [1], describing a clinically significant state with a limited number of metastases in a single or a limited number of organs. They also suggested that oligometastatic patients can be treated with local radical therapy (LRT) with radical intent but that further studies are needed to identify patients who will benefit the most [1]. Synchronous oligometastases is defined as a diagnosis of oligometastases at the first diagnosis of metastatic NSCLC.

Several, mainly retrospective series showed that a subset of these radically treated patients can indeed obtain a long-term survival, especially those with a single brain or adrenal metastasis and N0 disease [2–8]. The first prospective trial (single arm, phase II) was published in 2012 [9]. Eligible patients were those with stage IV NSCLC with less than five synchronous metastases, amenable for LRT. Eighty-seven percent of the included patients had a single metastasis, and 95% of them received chemotherapy as part of their primary treatment. Two- and three-year survival rates were 23.3% and 17.5%, respectively [9]. With the published series and the widespread introduction of minimal invasive surgery and stereotactic radiotherapy, the concept of delivering LRT in patients with oligometastatic NSCLC gained increasing interest and was also incorporated in NSCLC guidelines. For example, the European Society for Medical Oncology guideline states that definition for oligometastatic disease varies but that patients with one to three synchronous metastases can be treated with radical intent, preferably in a clinical trial [10]. The National Comprehensive Cancer Network guideline states that patients with NSCLC with limited metastases can receive LRT [11]. The 8th TNM classification of lung cancer also included the concept: M1b defines a single metastasis in a single site, and M1b patients were shown to have a superior prognosis than M1c patients, although treatment was not known for these patients [12]. After the first prospective phase II trial, three other trials including patients with synchronous oligometastatic NSCLC have been reported with promising progression-free survival (PFS) data [13–15]. Only for one trial, overall survival (OS) results have been reported, with a median OS of 41.2 months for the LRT arm and 17 months for the control arm [15]. The inclusion criteria such as the
number of metastases, considering the primary and/or mediastinal lymph nodes, eligibility of patients with driver mutations and treatment sequence varied (Table 1) [16].

As it is clear from these summarised trials and guidelines, definition of synchronous oligometastatic NSCLC varies. Furthermore, even though most trials allow at least three metastatic sites and do not restrict on mediastinal lymph nodes, most enrolled patients have only one metastatic site and N0-1 disease (Table 1) [13–15]. A single oligometastatic definition is, however, needed to design and compare trials. The European Organisation for Research and Treatment of Cancer Lung Cancer Group (EORTC-LCG) initiated a consensus process. A consensus group was formed aiming to agree on a common NSCLC synchronous oligometastatic definition that could be used in future clinical trials. In preparation for this meeting, a systematic review [17] and a survey [18] were performed. Furthermore, we redistributed a 2012 case-based survey (Dooms et al. [19], presented at the World Congress of Lung Cancer 2013) to a larger expert panel. This is to assess synchronous oligometastatic NSCLC definitions used by clinical experts in daily practice and its evolution. Results of this case-based survey are reported here.

2. Materials and methods

2.1. Cases

The original 2012 case-based survey was developed in preparation for a workshop on oligometastatic NSCLC in Leuven, Belgium, and consisted of ten real-life multidisciplinary team (MDT) discussed patients. These patients were in a good clinical condition, had no significant comorbidities and were all 18F-fluorodeoxyglucose positron emission tomography (18FFDG-PET) and brain magnetic resonance imaging (MRI) staged. All patients had less than five metastases, and nine of them had three or less metastases. Both oncogene-addicted (epidermal growth factor receptor [EGFR]–mutated) and wild-type NSCLC cases were included. The 7th TNM edition was initially used for these cases but was recoded to the 8th edition for this analysis [20,21]. The cases can be found in the supplementary material (appendix 1). These patients were diagnosed with stage IV NSCLC between 2009 and 2012; the last date of follow-up was January 5, 2018.

2.2. Distribution of cases

In 2012, this survey was sent to 11 experts in the field with the following questions: (1) Is this oligometastatic disease? And (2) Can you state what your preferred treatment is?

In December 2017, the same cases were distributed to 33 international NSCLC experts involved in the European Organisation for Research and Treatment of Cancer (EORTC) oligometastatic NSCLC consensus group (including four young investigators), with the following questions: (1) What is your working environment? (2) Can you please discuss these cases in your MDT? (3) Do these patients have oligometastatic disease? And (4) What is your treatment proposal for each...
oligometastatic case? Responders had the option to add remarks or comments regarding the way their decision was made. The responders were not aware of the actual treatment of the cases and did not know the 2012 answers. Current results were compared with the 2012 answers, and the real-life applied treatment and survival data of the patients were added (the last date of follow-up was January 5, 2018).

2.3. Statistics

Statistical analysis was performed with Excel 2016. Descriptive statistics were used to describe all answers to the cases, and the Fisher exact test was used to evaluate if the answer in 2017 (oligometastatic yes/no) was related to whether a case was discussed in the MDT.

3. Results

2012 and 2017 results plus real-life outcomes are summarised in Table 2. Detailed treatment answers (type of LRT, type of systemic treatment, sequence of treatment [if mentioned in the answer]) can be found in Supplemental Table 1.

3.1. 2012

In 2012, 11 experts (three radiation oncologists, three thoracic surgeons, three pulmonologists, one pathologist and one specialist in nuclear medicine) answered all ten cases. The answers are summarised in Table 1. Only one case (case 10) had 100% consensus that this was oligometastatic disease. For the other cases, agreement ranged from 36 to 91%. The number of treatment options per oligometastatic case ranged from two to six. The percentage of responders that included systemic treatment in their treatment proposal for the cases they considered oligometastatic ranged from 9 to 100%. The lowest percentage of systemic treatment use was found for the 100% oligometastatic consensus case 10 (cT1bN0M1b). Even though responders considered a case oligometastatic,
the percentage of treatment with radical intent (i.e. LRT given to all disease sites) for oligometastatic cases varied from 43 to 100%. The lowest percentage was found for case 6.

3.2. 2017 and comparison with 2012

In 2017, 26 of 33 (78.8%) experts from 24 different institutions (11 countries) responded and answered all cases. Six worked in a cancer centre, 19 in a university centre and one in a general hospital. One was a clinical oncologist, seven were medical oncologists, seven pulmonologists, seven radiation oncologists and four thoracic surgeons. Sixteen of them (62%) discussed all cases in their local MDT.

In general, remarks were made that in case of a solitary metastasis, pathology proof should be obtained when feasible. One respondent stated that mediastinoscopy was necessary in patients with N0/1 disease when mediastinoscopy was not already performed. When a case was not considered oligometastatic, reasons were the extent of locoregional disease, the number of metastases or their location (i.e. LRT not possible).

For the same patient case (number ten) as in 2012, there was 100% consensus in 2017 that this was oligometastatic disease. For the other cases, agreement ranged from 38 to 96%. The four cases with an agreement of more than 90% were cases with N0 or N1 disease (and one N2 case with a solitary micrometastasis in lymph node station 4R) and a single metastasis (one case with 2 brain metastases). There was no association between the decision that a case was oligometastatic and discussing the case in the MDT except for case 5. In case 5, 45% of those presenting the case in the MDT stated that it was oligometastatic disease while 80% not discussing in the MDT stated it was oligometastatic disease (p = 0.04).

For seven cases, the percentage of oligometastatic agreement did not differ for more than 5% when 2012 and 2017 answers were compared. For the other three cases, the percentage of oligometastatic agreement was 13–17% lower in 2017 than in 2012. In 2017, the number of treatment options ranged from three to eight, and for seven cases, this number was higher in 2017 than in 2012. The percentage of responders that included systemic treatment in 2017 was 54–100%. Systemic treatment was proposed as neoadjuvant, concurrent and adjuvant approaches (Supplemental Table 1). For two cases, the use of systemic treatment percentage was more than 5% lower than in 2012 (8% and 16%, respectively); for six, it was more than 5% higher (range, 11–45%). In 2017, the percentage of treatment with radical intent for the oligometastatic cases ranged from 60 to 100%, was 5% lower than in 2012 in one case and more than 5% higher in six cases (range 10–46%).

3.3. Real-life outcomes

In real life, seven patients were treated with radical intent (Table 2). Two of them were treated with induction chemotherapy followed by LRT, and the others were treated with LRT and concurrent or adjuvant systemic treatment. Three of these seven patients were alive at five years, and none of the non-radically treated patients were alive at five years. Patient six was treated with palliative chemotherapy only and died after 51.5 months of a second primary metastatic cholangiocarcinoma. In hindsight, it was possible that the liver lesions were metastases of a cholangiocarcinoma although median OS of a non-radically treated cholangiocarcinoma is less than one year [22]. Patient ten, with 100% oligometastatic consensus received radical treatment but died after 11.6 months (Table 1).

4. Discussion

With the introduction of minimally invasive LRT techniques and the superior survival outcomes with LRT added to systemic treatment [13,15,23], there is increased interest in radically treating (synchronous) patients with oligometastatic NSCLC. However, definition for synchronous oligometastatic NSCLC varies across guidelines and trials where only selected patients are included. Furthermore, more oligometastatic patients are treated with LRT in daily practice, and it is not known whether this type of oligometastatic patients treated mirrors that of the clinical trials.

We showed that the oligometastatic definition in daily clinical practice was conservative: even though all cases had less than five metastases and 90% had three or less metastases, only one case had 100% consensus that this was oligometastatic disease. Three other cases had more than 90% oligometastatic consensus: two of these cases had a solitary metastasis, the other had two brain metastases and all cases had N0 (or micrometastatic N) disease. The oligometastatic definition was more restrictive in 2017 than in 2012, but cases with the highest agreement on oligometastatic disease remained the same. The number of metastatic sites, mediastinal lymph node status and possibility for LRT seem to be components that are taken into account by experts for oligometastatic definition and treatment in daily practice.

Interestingly, there seems to be a discrepancy between a theoretical definition of oligometastatic disease (i.e. not linked to a specific patient case) and the practical definition of oligometastatic disease. This is shown for clinical trials as well as daily practice. Despite that most trials allow up to three or five metastatic sites (some even more) and do not restrict on the presence of mediastinal lymph node metastases, most enrolled patients have only one metastatic lesion and N0 or N1.
Better selection methods are needed to identify oligometastatic patients who will benefit from LRT in addition to systemic treatment. The number and sometimes also location of metastasis, volume of disease and nodal status are associated with the outcome in oligometastatic patients [3,6,7]. In the trial by Gomez et al. [15,23], only treatment type (LRT versus no LRT) and presence of driver mutations were associated with improved PFS. Other patient-related factors could not be identified, but the number of included patients in this trial was small. Iyengar et al. [13] analysed only prognostic factors for PFS within the LRT group. Hopefully the Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (SARON) trial (NCT02417662) will provide some of these answers because patients are stratified as per mediastinal lymph node status (N0-1 versus N2-3), histology (adenocarcinoma versus non-adenocarcinoma), brain metastases (present versus absent) and the number of oligometastatic sites (1 versus 2 versus 3) [27]. Other interesting factors such as (metabolic) volume of disease, radiomics features, molecular signatures (e.g. microRNA’s) and use of circulating tumour DNA to predict benefit of LRT in patients with oligometastatic NSCLC should be evaluated in future trials [9,28-35]. In addition, it should be evaluated whether the same predictive factors exist in patients treated with immunotherapy, as this will also be more incorporated in the treatment of patients with oligometastatic NSCLC.

5. Conclusion

In this case-based survey, oligometastatic NSCLC definition in daily practice was conservative. The number of metastases and organs involved, extent of locoregional disease and the possibility for radical treatment seem to be components of the daily practice oligometastatic definition. Efforts such as by the EORTC oligometastatic definition consensus group should be made to provide a uniform definition. This definition should be tested in future trials and in the OligoCare project. Furthermore, predictive factors for benefit of LRT should prospectively be evaluated.

Conflict of interest statement

T.B. reports no conflict of interest regarding the content of this manuscript. A.L., N.G.L., J.V., B.H., M.G.L. and C.D. report no conflict of interest. L.E.L.H. received research funding from Roche and Boehringer Ingelheim (both institution); has been a member of the advisory board of Boehringer and BMS, (both institution, BMS also self); has received travel reimbursement.
from Roche and BMS (self); has participated in a mentorship program with key opinion leaders funded by AstraZeneca and has received fees for educational webinars from Quadia (self). S.N. reports no conflict of interest related to the current manuscript. Outside of the current manuscript, S.N. has been a member of the advisory board of Abbvie, Boehringer Ingelheim, BMS, Celgene, Eli Lilly, MSD, Takeda, Roche and Pfizer. D.D.R. reports no conflict of interest related to the current manuscript. Outside of the current manuscript, D.D.R. has been a member of the advisory board of AstraZeneca, Bristol-Myers Squibb, Roche/Genentech, Merck/Pfizer, Celgene, Noxxon and Mologen and has received investigator-initiated grants from Bristol-Myers Squibb and Boehringer Ingelheim. A.-M.C.D. reports no conflict of interest related to the current manuscript. Outside of the current manuscript, A.-M.C.D. has been a member of the advisory board of BMS, MSD, Roche, Eli Lilly, Takeda, Pfizer, Clovis, AstraZeneca, AbbVie and Boehringer Ingelheim (all institution) and reports receiving grant from BMS (institution). B.B. reports no conflict of interest related to the current manuscript. Outside the current manuscript, B.B. received grants for clinical and translational research from AbbVie, Amgen, AstraZeneca, Biogen, Blueprint Medicines, BMS, Celgene, Eli Lilly, GSK, Igynta, IPSEN, Merck KGaA, MSD, Nektar, Onxeo, Pfizer, Pharma Mar, Sanofi, Spectrum Pharmaceuticals, Takeda and Tiziana Pharma.

**Funding**

This publication was supported by a donation from the ‘Kankerbestrijding/KWF’ from the Netherlands through the EORTC Cancer Research Fund. The funding source had influence whatsoever on design, collection, analysis and writing of the manuscript.

**Acknowledgements**

The authors thank the following experts for their evaluation and discussing the cases (2017; current authors not mentioned): T Cufer, S Senan, S Ekman, M Infante, P van Schil, R Rami-Porta, N Peled, C Faiivre-Finn, N Girard, M O’Brien, S Ramella, Y Lievens, L Greillier, L Paz-Ares, J Edwards, M Reck, M Guckenberger 2012 (current authors not mentioned): P De Leyn, C Deroose, J Pfannschmidt, K Kerr, F Lagerwaard, I Lopez-Guerra, E Smit.

**Appendix A. Supplementary data**

Supplementary data to this article can be found online at [https://doi.org/10.1016/j.ejca.2019.09.013](https://doi.org/10.1016/j.ejca.2019.09.013).

**References**

[1] Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol : Off J Am Soc Clin Oncol 1995;13:8–10.
[2] Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004;363:1665–72.
[3] Griffioen GH, Toguri D, Dahele M, Warner A, de Haan PF, Rodrigues GB, et al. Radical treatment of synchronous oligometastatic non-small cell lung carcinoma (NSCLC): patient outcomes and prognostic factors. Lung Cancer 2013;82:95–102.
[4] Porte H, Siat J, Guibert B, Lepimpiec-Barthes F, Jancovic R, Bernard A, et al. Resection of adrenal metastases from non-small cell lung cancer: a multicenter study. Ann Thorac Surg 2001;71:981–5.
[5] Tanveyronon T, Robinson LA, Schell MJ, Strong VE, Kapoor R, Coit DG, et al. Outcomes of adrenalectomy for isolated synchronous versus metachronous adrenal metastases in non-small-cell lung cancer: a systematic review and pooled analysis. J Clin Oncol: Offic J Am Soc Clin Oncol 2008;26:1142–7.
[6] Ashworth A, Rodrigues G, Boldt G, Palma D. Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature. Lung Cancer 2013;82:197–203.
[7] Ashworth AB, Senan S, Palma DA, Raquet M, Ahn YC, Ricardi U, et al. An individual patient data metaanalysis of outcomes and prognostic factors after treatment of oligometastatic non-small-cell lung cancer. Clin Lung Cancer 2014;15:546–55.
[8] Holy R, Piroth M, Pinkawa M, Ehle MJ. Stereotactic body radiation therapy (SBRT) for treatment of adrenal gland metastases from non-small cell lung cancer. Strahlenther Onkol 2011;187:245–51.
[9] De Ruyscher D, Wanders R, van Baardwijk A, Dingemans AM, Reymen B, Houben R, et al. Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450). J Thorac Oncol: Offic Publ Int Assoc Stud Lung Cancer 2012;7:1547–55.
[10] Planchar D, Popat S, Kerr K, Novello S, Smit EF, Faire-Finn C, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol: Offic J Eur Soc Med Oncol/ESMO 2018;29:v192–237.
[11] NCCN guidelines non-small cell lung cancer. 2019. 2019, version 2.
[12] Eberhardt W, Mitchell A, Crowley J, Kondo H, Kim Y, Turrisi A, et al. The IASLC Lung cancer staging project: proposals for the revision of the M descriptors in the forthcoming eighth edition of the TNM classification of lung cancer. J Thorac Oncol 2015;10:1515–22.
[13] Iyengar P, Wardak Z, Gerber DE, Tumati V, Ahn C, Hughes RS, et al. Consolidative radiotherapy for limited metastatic non-small cell lung cancer: a phase 2 randomized clinical trial. JAMA Oncol 2018;4:e173501.
[14] Bauml J, Mick R, Ciunci C, Aggarwal C, Davis C, Evans T, et al. Phase II study of pembrolizumab for oligometastatic Non-small cell lung cancer (NSCLC) following completion of locally ablative therapy (LAT). J Thorac Oncol 2018;13:S335–56.
[15] Gomez DR, Tang C, Zhang J, Blumenschein Jr GR, Hernandez M, Lee JJ, et al. Local consolidative therapy vs. Maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer: long-term results of a multi-institutional, phase II, randomized study. J Clin Oncol: Offic J Am Soc Clin Oncol 2019;37:1558–65.
[16] Dingemans A, Hendriks L, Berghmans T, Levy A, Hasan B, Faiivre-Finn C, et al. MA25.02 - searching for a definition of
synchronous oligometastatic (sOMD)-NSCLC: a consensus from thoracic Oncology experts. J Thorac Oncol 2018;10. S446.

[17] Giaj-Levra N, Levra MG, Durieux V, Novello S, Besse B, Hasan B, et al. Defining synchronous oligometastatic non-small cell lung cancer: a systematic review. J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer 2019 Jun 11. https://doi.org/10.1016/j.jtho.2019.05.037. pii: S1556-0864(19)30458-7. [Epub ahead of print].

[18] Levy A, Hendriks LE, Berghmans T, Faivre-Finn C, Giaj-Levra N, Levra MG, Durieux V, Novello S, Besse B, Dooms C, De Leyn P, Deroose C, De Ruysscher D, Goldstraw P, Crowley J, Chansky K, Giroux DJ, Groome PA, Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, et al. Strategies and technical challenges for imaging oligometastatic disease: recommendations from the European Organisation for Research and Treatment of Cancer imaging group. Eur J Cancer 2018;91:153–63.

[19] De Ruyscher D, Wanders R, Hendriks LE, van Baardwijk A, Reynen B, Houben R, et al. Progression-Free-Surival and Overall Survival beyond 5 years of non-small cell lung cancer patients with synchronous oligometastases treated in a prospective phase II trial (NCT 01282450). J Thorac Oncol : Offic Publ Int Assoc Stud Lung Cancer 2018:13:1958–61.

[20] Conibeer J, Chia B, Ngai Y, Bates AT, Counsell N, Patel R, et al. Study protocol for the SARON trial: a multicentre, randomised controlled phase III trial comparing the addition of stereotactic ablative radiotherapy and radical radiotherapy with standard chemotherapy alone for oligometastatic non-small cell lung cancer. BMJ Open 2018;8:e020690.

[21] Zhang H, Wroblewski K, Jiang Y, Penney BC, Appelbaum D, Simon CA, et al. A new PET/CT volumetric prognostic index for non-small cell lung cancer. Lung Cancer 2015;89:43–9.

[22] Im HJ, Pak K, Cheon GJ, Kang KW, Kim SJ, Kim JI, et al. Prognostic value of volumetric parameters of (18)F-FDG PET in non-small-cell lung cancer: a meta-analysis. Eur J Nucl Med Mol Imaging 2015;42:241–51.

[23] Wong AC, Watson SP, Pitroda SP, Son CH, Das LC, Stuck ME, et al. Clinical and molecular markers of long-term survival after oligometastasis-directed stereotactic body radiotherapy (SBRT). Cancer 2016;122:2242–50.

[24] Uppal A, Wightman SC, Mallon S, Oshima G, Pitroda SP, Zhang Q, et al. 14q32-encoded microRNAs mediate an oligometastatic phenotype. Oncotarget 2015;6:3540–52.

[25] Lussier YA, Khodarev NN, Regan K, Corbin K, Li H, Ganai S, et al. Oligo- and polymetastatic progression in lung metastasis(es) patients is associated with specific microRNAs. PLoS One 2012;7:e50141.

[26] Jensen GL, Mackin DS, Fried DV, Zhou S, Court LE, et al. Prognostic value of combining a quantitative image feature from positron emission tomography with clinical factors in oligometastatic non-small cell lung cancer. Radiother Oncol 2018;126:362–7.

[27] Perez-Ramirez C, Canadas-Garre M, Robles AL, Molina MA, Faus-Dader MJ, Calleja-Hernandez MA. Liquid biopsy in early stage lung cancer. Transl Lung Cancer Res 2016;5:517–24.

[28] Bauml J, Mick R, Ciunci A, Aggarwal C, Evans T, Miller L, et al. OA 17.08 phase II study of pembrolizumab for oligometastatic non-small cell lung cancer (NSCLC) following completion of locally ablative therapy (LAT). J Thorac Oncol 2017;12. S1794–S5.

[29] deSouza NM, Liu Y, Chiti A, Oprea-Lager D, Gebhart G, Van Beers BE, et al. Strategies and technical challenges for imaging